Rep. Jared Moskowitz Purchases Shares of AbbVie Inc. (NYSE:ABBV)

Representative Jared Moskowitz (D-Florida) recently bought shares of AbbVie Inc. (NYSE:ABBV). In a filing disclosed on February 10th, the Representative disclosed that they had bought between $1,001 and $15,000 in AbbVie stock on January 15th. The trade occurred in the Representative’s “MORGAN STANLEY ACTIVE ASSETS (1)” account.

Representative Jared Moskowitz also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of McKesson (NYSE:MCK) on 1/15/2025.
• Sold $1,001 – $15,000 in shares of Canadian National Railway (NYSE:CNI) on 1/15/2025.
• Purchased $1,001 – $15,000 in shares of Stryker (NYSE:SYK) on 1/15/2025.
• Purchased $1,001 – $15,000 in shares of The Goldman Sachs Group (NYSE:GS) on 1/15/2025.
• Sold $1,001 – $15,000 in shares of Merck & Co., Inc. (NYSE:MRK) on 1/15/2025.
• Sold $1,001 – $15,000 in shares of Abbott Laboratories (NYSE:ABT) on 1/15/2025.

AbbVie Stock Performance

AbbVie stock traded up $0.12 during midday trading on Thursday, hitting $193.12. The stock had a trading volume of 1,230,423 shares, compared to its average volume of 5,854,912. AbbVie Inc. has a 52-week low of $153.58 and a 52-week high of $207.32. The company has a market capitalization of $341.27 billion, a PE ratio of 80.45, a P/E/G ratio of 1.53 and a beta of 0.58. The firm’s fifty day moving average is $178.24 and its two-hundred day moving average is $185.91. The company has a current ratio of 0.65, a quick ratio of 0.54 and a debt-to-equity ratio of 9.64.

AbbVie (NYSE:ABBV) last released its quarterly earnings data on Friday, January 31st. The company reported $2.16 earnings per share for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.82). AbbVie had a return on equity of 257.91% and a net margin of 7.59%. During the same period in the prior year, the business posted $2.79 earnings per share. On average, research analysts forecast that AbbVie Inc. will post 12.32 EPS for the current year.

Institutional Investors Weigh In On AbbVie

Hedge funds have recently modified their holdings of the business. Straightline Group LLC purchased a new position in AbbVie during the fourth quarter valued at approximately $242,000. Bernard Wealth Management Corp. bought a new stake in AbbVie during the fourth quarter valued at about $610,000. German American Bancorp Inc. raised its holdings in AbbVie by 1.1% in the fourth quarter. German American Bancorp Inc. now owns 27,684 shares of the company’s stock worth $4,919,000 after purchasing an additional 302 shares in the last quarter. Abacus FCF Advisors LLC boosted its holdings in shares of AbbVie by 66.0% in the 4th quarter. Abacus FCF Advisors LLC now owns 105,173 shares of the company’s stock valued at $18,689,000 after buying an additional 41,802 shares in the last quarter. Finally, Canopy Partners LLC raised its stake in shares of AbbVie by 33.9% during the 4th quarter. Canopy Partners LLC now owns 5,832 shares of the company’s stock worth $1,036,000 after acquiring an additional 1,476 shares in the last quarter. Hedge funds and other institutional investors own 70.23% of the company’s stock.

Insider Transactions at AbbVie

In other news, SVP Kevin K. Buckbee sold 1,800 shares of the firm’s stock in a transaction dated Monday, December 16th. The stock was sold at an average price of $172.24, for a total value of $310,032.00. Following the completion of the transaction, the senior vice president now directly owns 6,983 shares in the company, valued at $1,202,751.92. This trade represents a 20.49 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders own 0.25% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have recently commented on ABBV. Wells Fargo & Company increased their target price on AbbVie from $195.00 to $210.00 and gave the company an “overweight” rating in a research report on Monday, February 3rd. Guggenheim increased their price objective on shares of AbbVie from $212.00 to $214.00 and gave the company a “buy” rating in a research report on Monday, February 3rd. Piper Sandler lifted their price objective on shares of AbbVie from $212.00 to $220.00 and gave the stock an “overweight” rating in a research note on Tuesday, December 17th. Citigroup upped their target price on shares of AbbVie from $205.00 to $215.00 and gave the company a “buy” rating in a research report on Monday, February 3rd. Finally, Raymond James reiterated an “outperform” rating and issued a $220.00 price target (up previously from $218.00) on shares of AbbVie in a research report on Monday, February 3rd. Five investment analysts have rated the stock with a hold rating, seventeen have given a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $208.35.

About Representative Moskowitz

Jared Evan Moskowitz (Democratic Party) is a member of the U.S. House, representing Florida’s 23rd Congressional District. He assumed office on January 3, 2023. His current term ends on January 3, 2027.

Moskowitz (Democratic Party) is running for re-election to the U.S. House to represent Florida’s 23rd Congressional District. He declared candidacy for the 2026 election.

Jared Evan Moskowitz was born in Coral Springs, Florida. Moskowitz graduated from Marjory Stoneman Douglas High School. He earned a bachelor’s degree in political science and government from George Washington University in 2003 and a law degree from Nova Southeastern University in 2007. Moskowitz’s career experience includes working as the director of the Florida Division of Emergency Management and general counsel with AshBritt Inc.

AbbVie Company Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.